Press releases

Filter by year

  • Dec 23, 2020
    Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bl…
  • Nov 24, 2020
    Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain D…
  • Nov 19, 2020
    Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
  • Nov 12, 2020
    Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
  • Nov 10, 2020
    Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
  • Nov 02, 2020
    Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
  • Oct 27, 2020
    Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
  • Oct 07, 2020
    Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
  • Sep 08, 2020
    Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference
  • Aug 13, 2020
    Urovant Sciences Reports Fiscal First Quarter 2020 Results
  • Aug 06, 2020
    Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
  • Jun 18, 2020
    Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
  • Jun 18, 2020
    Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
  • Jun 11, 2020
    Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results
  • Jun 02, 2020
    Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market…
  • May 27, 2020
    Urovant Sciences Appoints James Hindman to Board of Directors
  • May 26, 2020
    Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
  • May 14, 2020
    Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urologi…
  • Mar 23, 2020
    Urovant Sciences Appoints James Robinson as President and Chief Executive Officer
  • Mar 05, 2020
    Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
  • Mar 02, 2020
    Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology
  • Feb 25, 2020
    Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference
  • Feb 13, 2020
    Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
  • Feb 06, 2020
    Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results
  • Feb 04, 2020
    Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Ov…
  • Jan 17, 2020
    Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell
  • Jan 08, 2020
    Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference